Tirzepatide is a once-weekly injectable medication that functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By activating these receptors, tirzepatide enhances insulin secretion, suppresses glucagon release, and slows gastric emptying, leading to improved blood sugar control and reduced appetite. Clinical studies have demonstrated significant weight loss in individuals using tirzepatide alongside a healthy diet and exercise regimen. Available under brand names such as Mounjaro and Zepbound, tirzepatide offers a promising option for those seeking medical assistance in their weight management and diabetes treatment journey.
Tirzepatide mimics the action of GIP and GLP-1 hormones, which regulate appetite and food intake. By activating these receptors, it increases insulin secretion, decreases glucagon release, and slows gastric emptying, leading to reduced hunger and increased feelings of fullness.
Common side effects include nausea, vomiting, diarrhea, decreased appetite, and constipation. These gastrointestinal symptoms are often mild and tend to decrease over time as the body adjusts to the medication.
Tirzepatide is suitable for adults with type 2 diabetes seeking improved blood sugar control, as well as individuals with obesity or overweight conditions aiming for weight loss. A healthcare provider can assess individual suitability based on medical history and health goals.
Weight loss and improved blood sugar control can begin within the first few weeks of treatment, with significant results typically observed after several months. Long-term use, in conjunction with a healthy diet and exercise, is recommended for sustained benefits.